

Publication of 2016 Registration Document

Paris (France), April 25, 2017 – 5.45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company's 2016 Registration Document.

The 2016 Registration Document, filed with the French Market Authorities (*Autorité des Marchés Financiers*) on April 24, 2017, is available to the public free of charge upon request, as per current legal regulations, at Onxeo's headquarters – 49 Boulevard du Général Martial Valin, 75015 Paris – and on the Company's website: <http://www.onxeo.com/en/investisseurs/resultats-et-publications>.

The annual financial report, the report of the Chairman of the Board of Directors on corporate governance and internal control and risk management procedures as well as the related auditors' reports and information on the fees paid to the statutory auditors in 2016 are included in this Registration Document

About Onxeo

Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry.

Onxeo's objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers.

Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications.

The Company is headquartered in Paris, France with offices in Copenhagen and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596).

Learn more by visiting www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2016 Registration Document filed with the AMF on April 24, 2017, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website (www.onxeo.com).



Onxeo

Valerie Leroy,
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00

Media Relations

Caroline Carmagnol / Simon Derbanne -
Alize RP
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 6 38 16 26 41

Investor Relations / Strategic Communications

Dušan Orešanský / Emmanuel Huynh –
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92

Investor Relations US

Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
+1 212 915 2578